Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Christopher Buckley joins the Kennedy Institute as a new Director of Clinical Research from May 2017.

Christopher Buckley joins the Kennedy Institute as a new Director of Clinical Research from May 2017.

Chris joins the Kennedy Institute from the University of Birmingham, where he was previously Arthritis Research UK Professor of Rheumatology. In this new post as Kennedy Professor of Translational Rheumatology he takes up a joint appointment between the two universities; as director of Clinical Research at the Kennedy Institute in Oxford and Director of the NIHR Wellcome Trust Clinical Research Facility in Birmingham.

In his new position Chris will oversee the Arthritis Therapy Acceleration Programme (A-TAP), a translational research initiative aimed at speeding up the development and testing of new therapies for joint and related inflammatory diseases. He will also lead a research group at the Kennedy Institute focused on stromal cell biology and inflammatory disease. The A-TAP brings together basic science at the Kennedy Institute with clinical research capabilities at the Botnar Research Centre (Oxford) and the Institute of Translational Medicine (Birmingham).

Chris will facilitate the development of a partnership of clinical colleagues at five different NHS organizations along the M40 corridor. These include the Nuffield Orthopaedic Hospital, John Radcliffe Hospital, University Hospitals Coventry and Warwickshire, University Hospitals Birmingham, Sandwell and West Birmingham Hospitals incorporating the Modality Primary Care Vanguard service.  This “M40 alliance” will establish a network of clinical centres, covering over 6 million people along the M40 corridor allowing  enhanced access to patient cohorts and tissue samples to enable translational research to dissect molecular drivers of disease.  It will allow the design and delivery of experimental medicine studies to test new drugs in carefully selected patient populations at pace, at scale and on time. As Chris says “cohorts are kings; biomarkers are beggars; data is dynamite”

Professor Fiona Powrie, Director of the Kennedy Institute, said: “The partnership between the Universities of Oxford and Birmingham will harness the existing research strengths of both universities in order to accelerate the development and testing of new therapies for patients. The Arthritis Therapy Acceleration Programme (A-TAP) will develop and test therapies based on the underlying causes of inflammatory disease, rather than simply treating their clinical symptoms”

Speaking of his new position, Chris explains: 'The current rate limiting step in experimental medicine is not how to design new and safe drugs but how to improve their efficacy beyond the current best treatments. We also don’t know how to best match the right drug to the right disease. Our A-TAP will use strategies that have worked in the cancer field to both repurpose drugs to new indications, as well as use innovative concepts in trial design such as “cluster trials” where one drug is tried out in a range of different inflammatory diseases at an early stage. This process-driven-pathway- focused approach to the four immune mediated inflammatory diseases to be studied in the A-TAP (rheumatoid arthritis, sjogrens syndrome, spondyloarthropathy and inflammatory bowel disease)  will help us work out which drug is most likely to work for which disease at a much earlier stage than is currently possible.'

So what can you expect to see develop in the next 12 months? “We need more clinical fellows working with basic scientists in the Kennedy Institute to encourage a culture of translation” explains Chris. “Breaking down the silos between bedside and bedside is just as important as between the bench and the bedside. Removing these silos will encourage a more process drive approach to inflammation, fibrosis and repair; three key pillars of research at the Kennedy Institute. We have much to learn across clinical disciplines; that’s what the therapeutic use of biologics has taught us. Shared processes across different organs mean that we need clinical fellows from different disciplines working on the common process that underpin inflammation, fibrosis and repair. This might even lead to a new taxonomic approach to disease, based on underlying pathogenic drivers, rather than just the clinical symptoms in the organs in which disease first presents. Only then can we expect to see the molecular marker match the pathogenic mechanism”.

The ATAP is funded by a £7m strategic award from the Kennedy Trust for Rheumatology Research. 

Similar stories

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers at NDORMS have developed a new set of guidelines for reporting mediation analyses in health research.

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS.

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Unlocking the secrets of the microbiome

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.

Into the future: watching biology unfold

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.